Literature DB >> 16541083

Anxiolytic-like properties of the anandamide transport inhibitor AM404.

Marco Bortolato1, Patrizia Campolongo, Regina Anne Mangieri, Maria Luisa Scattoni, Roberto Frau, Viviana Trezza, Giovanna La Rana, Roberto Russo, Antonio Calignano, Gian Luigi Gessa, Vincenzo Cuomo, Daniele Piomelli.   

Abstract

The endocannabinoids anandamide and 2-arachidonoyglycerol (2-AG) may contribute to the regulation of mood and emotion. In this study, we investigated the impact of the endocannabinoid transport inhibitor AM404 on three rat models of anxiety: elevated plus maze, defensive withdrawal and separation-induced ultrasonic vocalizations. AM404 (1-5 mg kg(-1), intraperitoneal (i.p.)) exerted dose-dependent anxiolytic-like effects in the three models. These behavioral effects were associated with increased levels of anandamide, but not 2-AG, in the prefrontal cortex and were prevented by the CB(1) cannabinoid antagonist rimonabant (SR141716A), suggesting that they were dependent on anandamide-mediated activation of CB(1) cannabinoid receptors. We also evaluated whether AM404 might influence motivation (in the conditioned place preference (CPP) test), sensory reactivity (acoustic startle reflex) and sensorimotor gating (prepulse inhibition (PPI) of the startle reflex). In the CPP test, AM404 (1.25-10 mg kg(-1), i.p.) elicited rewarding effects in rats housed under enriched conditions, but not in rats kept in standard cages. Moreover, AM404 did not alter reactivity to sensory stimuli or cause overt perceptual distortion, as suggested by its lack of effect on startle or PPI of startle. These results support a role of anandamide in the regulation of emotion and point to the anandamide transport system as a potential target for anxiolytic drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16541083     DOI: 10.1038/sj.npp.1301061

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  76 in total

1.  Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid system-related genes in the rat amygdala.

Authors:  Antonia Serrano; Patricia Rivera; Francisco J Pavon; Juan Decara; Juan Suárez; Fernando Rodriguez de Fonseca; Loren H Parsons
Journal:  Alcohol Clin Exp Res       Date:  2011-12-05       Impact factor: 3.455

Review 2.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

Review 3.  Enhancement of endocannabinoid signaling and the pharmacotherapy of depression.

Authors:  Regina A Mangieri; Daniele Piomelli
Journal:  Pharmacol Res       Date:  2007-09-11       Impact factor: 7.658

Review 4.  The endocannabinoid system as a target for the treatment of cannabis dependence.

Authors:  Jason R Clapper; Regina A Mangieri; Daniele Piomelli
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

5.  Upregulation of Anandamide Hydrolysis in the Basolateral Complex of Amygdala Reduces Fear Memory Expression and Indices of Stress and Anxiety.

Authors:  Maria Morena; Robert J Aukema; Kira D Leitl; Asim J Rashid; Haley A Vecchiarelli; Sheena A Josselyn; Matthew N Hill
Journal:  J Neurosci       Date:  2018-12-20       Impact factor: 6.167

Review 6.  The endocannabinoid system in brain reward processes.

Authors:  M Solinas; S R Goldberg; D Piomelli
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

7.  Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal behavioral study in Wistar rats.

Authors:  Viviana Trezza; Patrizia Campolongo; Tommaso Cassano; Teresa Macheda; Pasqua Dipasquale; Maria Rosaria Carratù; Silvana Gaetani; Vincenzo Cuomo
Journal:  Psychopharmacology (Berl)       Date:  2008-05-02       Impact factor: 4.530

Review 8.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

9.  AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking.

Authors:  Islam Gamaleddin; Mihail Guranda; Maria Scherma; Walter Fratta; Alexandros Makriyannis; Subramanian K Vadivel; Steven R Goldberg; Bernard Le Foll
Journal:  J Psychopharmacol       Date:  2013-02-20       Impact factor: 4.153

10.  Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice.

Authors:  Adriana M Marques; Michele V Macena; Aline R Cardoso; Camila S O Hammes; Fernanda M L Pinheiro; Newton G Castro; Gilda A Neves
Journal:  Psychopharmacology (Berl)       Date:  2020-02-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.